19
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10425 |
AZ084
|
CCR | Immunology/Inflammation; Microbiology/Virology |
AZ084 是可口服的选择性 CCR8变构拮抗剂,其Ki 值为 0.9 nM,可研究哮喘。 | |||
T2036 |
6-OAU
GTPL5846 |
GPR | Endocrinology/Hormones; GPCR/G Protein |
6-OAU (GTPL5846) 是 GPR84 的替代激动剂,在 Gqi5 嵌合体存在的情况下,在 HEK293 细胞中激活人 GPR84,在 PI 测定中 EC50 为 105 nM。 | |||
T69911 | CU-6PMN | ||
CU-6PM is a new fluorescent RXR agonist. CU-6PMN was designed based on the fact that umbelliferone emits strong fluorescence in a hydrophilic environment, but the fluorescence intensity decreases in hydrophobic environments such as the interior of proteins. The developed assay CU-6PMN enabled screening of rexinoids to be performed easily within a few hours by monitoring changes of fluorescence intensity with widely available fluorescence microplate readers, without the need for processes such a... | |||
T6243 |
U-73122
U73122 |
Phospholipase; Ferroptosis; Lipoxygenase | Apoptosis; Metabolism |
U-73122 (U73122) 是一种磷脂酶 C 和 5-脂氧合酶抑制剂,对磷脂酶 C 的 IC50值约为 1-2.1 µM。它是一种 PLC 抑制剂,可减少激动剂诱导的血小板和 PMN 中的 Ca2+ 增加。 | |||
T33431 |
MK-287
L680573,L 680573,L-680573 |
||
MK-287 (L-680573) is a platelet activator (PAF) antagonist that effectively inhibates the binding of [3H]C18-PAF to human platelets, polynucleated white blood cells (PMN), and pulmonary membranes. May be used to treat asthma, | |||
T22526 |
BML-111
5(S),6(R)-7-trihydroxymethyl Heptanoate |
Others | Others |
inhibits leukotriene B4 (LTB4)-induced polymorphonuclear neutrophils (PMN) chemotaxis | |||
T36043 |
17(R)-Protectin D1
17(R)-Protectin D1 |
||
17(R)-Protectin D1 is an aspirin-triggered epimer of the specialized pro-resolving mediator protectin D1 .1It decreases leukotriene B4-induced transendothelial migration of human polymorphonuclear (PMN) neutrophils when used at concentrations ranging from 0.1 to 10 nM. 17(R)-Protectin D1 (0.01-10 ng) reduces the recruitment of neutrophils in a mouse model of TNF-α-induced peritonitis. 1.Serhan, C.N., Fredman, G., Yang, R., et al.Novel proresolving aspirin-triggered DHA pathwayChem. Biol.18(18)97... | |||
T37460 |
Lipoxin B4
Lipoxin B4 |
||
Lipoxin B4 (LXB4) is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15(S)-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 and inhibits LTB4-induced adhesion of PMNs with an IC50 value of 0.3 nM. | |||
T38308 |
Lipoxin B4 methyl ester
|
||
Lipoxin B4 (LXB4) methyl ester is a lipid soluble prodrug form of the transcellular metabolite LXB4 . LXB4 is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 and inhibits LTB4-induced adhesion of PMNs with an IC50 value of 0.3 nM. | |||
T28933 |
TCV-309
TCV309 |
||
TCV-309 is an inhibitor of platelet activating factor (PAF). TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. TCV-309 attenuates the priming effects of bronchoalveolar macrophages | |||
TP1864 |
[Glu1]-Fibrinopeptide B
[Glu1]-纤维蛋白肽B |
||
[Glu1]-Fibrinopeptide B, a derivative of fibrinopeptide B amino acid residues 1-14, originates from human fibrinopeptide B (hFpB). hFpB is a proteolytic cleavage product of the fibrinogen B beta-chain, specifically generated by thrombin, which plays a significant role in activating neutrophils (PMN), monocytes, and fibroblasts. | |||
T37259 | 14(S)-HDHA | ||
Docosahexaenoic acid is a nutritionally-derived ω-3 fatty acid that is abundant in the brain and the retina and is thought to be important in early development and for therapeutic approaches to inflammatory disorders and cancer. 14(S)-HDHA is an oxygenation product of DHA that serves as a precursor to maresin 1 , an anti-inflammatory, pro-resolving mediator that prevents polymorphonuclear neutrophil (PMN) infiltration and stimulates macrophage phagocytosis. At doses as low as 0.2 ng/mouse 14(S)-... | |||
T36017 |
PF-05381941
|
||
PF-05381941 is a potent dual inhibitor of TAK1/p38α, with IC50s of 156 and186 nM, respectively[1]. PF-05381941 inhibits LPS-stimulated release of TNF-αfrom human peripheralmononuclear (PMN) cells with an IC50 of 8 nM[1]. [1]. Kilty I, et al. TAK1 inhibition in the DFG-out conformation. Chem Biol Drug Des. 2013;82(5):500-505. | |||
T37166 |
RCTR1
|
||
Resolvin conjugate in tissue regeneration 1 (RCTR1) is a specialized pro-resolving mediator (SPM) biosynthesized from docosahexaenoic acid by isolated human macrophages and apoptotic polymorphonuclear (PMN) neutrophils.1It has been found in human spleen and bone marrow.2RCTR1 is produced via lipoxygenase-mediated oxidation of DHA to 7(S)-8-epoxy-17(S)-HDHA, which is conjugated to glutathione.1,2,3RCTR1 (10 nM) increases phagocytosis ofE. colior apoptotic neutrophils in isolated human monocyte-de... | |||
T71303 |
Flufenamic Acid-d4
|
||
Flufenamic acid-d4 is intended for use as an internal standard for the quantification of flufenamic acid by GC- or LC-MS. Flufenamic acid is a non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (IC50s = 3 and 9.3 µM for human COX-1 and COX-2, respectively). Flufenamic acid inhibits TNF-α-induced increases in COX-2 levels and NF-κB activation in HT-29 colon cancer cells in a concentration-dependent manner. It inhibits calcium influx induced by fMLP or A23187 in human polymorphonuclear... | |||
T35881 |
Resolvin E2
|
||
Resolvin E2 (RvE2) is a member of the specialized pro-resolving mediator (SPM) family of bioactive lipids.1It is produced from eicosapentaenoic acidviaan 18-HEPE intermediate, which is formed by aspirin-acetylated COX-2-mediated oxidation of EPA, by 5-lipoxygenase (5-LO) in human polymorphonuclear (PMN) neutrophils.2,3RvE2 (20 ng/animal) inhibits increases in inflammatory exudate neutrophil infiltration in a mouse model of peritonitis induced by zymosan A .3Hepatic RvE2 levels are increased in m... | |||
T35946 |
17(R)-Resolvin D1
Aspirin-triggered Resolvin D1,17(R)-Resolvin D1 |
||
Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid and docosahexaenoic acid.[1] In addition to being anti-inflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.[2] Resolvin D1 is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase.[1] 17(R)-RvD1 is an aspirin-triggered epimer of RvD1 that reduces human polymorphonuclear leukocyte (PMN) transendothelial migration, the ear... | |||
T38043 |
Resolvin E4
|
||
Resolvin E4 (RvE4) is a member of the specialized pro-resolving mediator (SPM) family of bioactive lipids.1It is produced from eicosapentaenoic acid by 15-lipoxygenase (15-LO)via15(S)-HpEPE and 15S-hydroxy, 5S-HpEPE intermediatesin vitroand by isolated human M2 macrophages or polymorphonuclear (PMN) neutrophils under normoxic or hypoxic conditions. RvE4 synthesis is enhanced in M2 macrophage and neutrophil co-cultures, indicating transcellular biosynthesis by a potential 15-LO and 5-LO mechanism... | |||
T83669 |
PMX-53 TFA
AcPhe-[Orn-Pro-D-Cyclohexylalanine-Trp-Arg],AcF-[OPdChaWR],3D53 |
||
PMX-53是一种大环型补体5a (C5a) 类肽模拟物及C5a受体的拮抗剂(IC50 = 0.3 µM)。它能抑制C5a诱导的人类分离性多形核白细胞(PMNs)中的髓过氧化物酶(MPO)分泌。在大鼠腹膜亚瑟斯反应模型中,PMX-53(10 mg/kg, p.o.)能够抑制血管渗漏、多形核白细胞浸润以及腹膜TNF-α和IL-6的产生。在3-硝基丙酸(3-NP)诱导的亨廷顿病大鼠模型中,它能减少体重损失和厌食,抑制纹状体退化。PMX-53(3 mg/kg)还能在ApoE-/-小鼠中减小动脉粥样硬化斑块大小和脂质含量。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4S1615 |
Sanggenon C
桑根酮C,桑根酮 C,Sanggenone C |
NF-κB | NF-κB |
Sanggenon C (Sanggenone C) 是一种从桑属的根皮中分离得到的黄烷酮 Diels-Alder 加合物化合物。它可抑制NF-κB 活性,抑制 RAW264.7 细胞中诱导型一氧化氮合酶的表达,以及肿瘤坏死因子-α 刺激的细胞粘附和血管细胞粘附分子-1 的表达。 它具有抗氧化和抗炎作用,也有抑制胰脂肪酶作用。 | |||
T16733 |
Resolvin E1
RvE1 |
Others | Others |
Resolvin E1 is an effective endogenous pro-resolving mediator of inflammation. Resolvin E1 has unique counterregulatory actions that inhibit PMN transendothelial migration. Resolvin E1 also acts as an effective inhibitor of leukocyte infiltration, dendrit |